This is a preview of subscription content, log in via an institution to check access.
References
Cleemput I, Thiry N. Cost-effectiveness evaluation of a quadrivalent human papillomavirus vaccine in Belgium [letter]. Pharmacoeconomics 2009; 27 (5): 433
Annemans L, Rémy V, Oyee J, et al. Cost-Effectiveness evaluation of a quadrivalent human papillomavirus vaccine in Belgium. Pharmacoeconomics 2009; 27 (3): 231–45
Jit M, Choi YH, Edmunds WJ. Economic evaluation of human papillomavirus vaccination in the United Kingdom. BMJ 2008; 337 (7665): 331–5
Kim JJ, Goldie SJ. Health and economic implications of HPV vaccination in the United States. N Engl J Med 2008 Aug 21; 359 (8): 821–32
Smith JS, Lindsay L, Hoots B, et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 2007; 121 (3): 621–32
Thiry N, De Laet C, Hulstaert F, et al. Cost effectiveness of human papillomavirus vaccination in Belgium: do not forget about cervical cancer screening. Int J Technol Assess Health Care 2009 Apr; 25 (2): 161–70
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Annemans, L. The Author’s Reply. Pharmacoeconomics 27, 433–434 (2009). https://doi.org/10.2165/00019053-200927050-00009
Published:
Issue Date:
DOI: https://doi.org/10.2165/00019053-200927050-00009